Breyanzi achieved a 95.5% response rate in relapsed or refractory marginal zone lymphoma, with 62.1% complete responses and 88.6% ongoing at 24 months. The therapy maintained a consistent safety ...

Patients with advanced marginal zone lymphoma (MZL) now have a CAR T-cell therapy with the FDA approval of lisocabtagene maraleucel (liso-cel, Breyanzi). "Patients living with marginal zone lymphoma .

The FDA accepted Breyanzi's sBLA for relapsed/refractory marginal zone lymphoma, granting priority review with a PDUFA date of December 5, 2025. Breyanzi is a CAR-T cell therapy targeting CD19, with a ...

MIAMI, FLORIDA (STRICTLY EMBARGOED UNTIL DEC. 8, 2024, AT 12 NOON EST) – Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with ...

Association between progression-free survival and overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era: A surrogate endpoint analysis. This is an ASCO Meeting ...